Spot on as usual JDP.
A few years ago, the risk ranking was:
1. Execution (includes misalignment of management)
2. Successful hostile bid
3. Science
IMO the current risk ranking is:
1. Successful hostile bid
2. Execution (e.g. carelessly dropping fragile test tubes etc)
3. Keyman risk
Thanks to our preclinicals, independent preclinicals, Sheba 1 and 2, science is no longer on the top risks list.
The main questions are:
* whether the new owner would retain RAC's scientists? They'd be crazy not to.
* will the new owner be a listed company? Bad luck for RAC shareholders if they aren't.
General Comments / Chat, page-10144
-
- There are more pages in this discussion • 1,134 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
0.000(0.00%) |
Mkt cap ! $245.3M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7352 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 160 | 1 |
View Market Depth
| Last trade - 10.06am 12/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |
Day chart unavailable